Analysis of Vaccination Background in Children Undergone SARS-CoV-2 Infection

Nowadays all news about the new coronavirus disease type arouses interest and concern among specialists around the world. Children often are not exposed to the COVID-19 virus or they just have mild course of the disease according to currently available data. These data may also explain why children have much lower incidence of COVID-19 in comparison to adults. The results of epidemiological observations performed by different researchers’ groups on the likely “protective” effect of routine vaccine prevention programs against new type of coronavirus disease led to initiation of clinical studies. This article presents the analysis of the vaccinal status and characteristics of vaccination and any other background in 143 Moscow children undergone SARS-CoV-2 infection. Overall, the general vaccination background in children who have undergone COVID-19 is characterized with low vaccination level and mismatch with the National Immunization Schedule. The most unfavorable vaccination background was mentioned in infants. The vaccination rate in all children of the first year of life (in 100% of cases) had gap to the routine schedule. The lowest rate of appropriate vaccination was recorded in case of viral poliomyelitis (in 30% of children) in reconvalescents new type of coronavirus disease. The vast majority of children undergone COVID-19 were not vaccinated against flue, only a few were vaccinated against pneumococcal infection. Now there are several studies focused on determining the protective role of vaccines in relation to the new type of coronavirus disease morbidity and course severity.

1. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS. 2020;117(30):17720–17726. doi: 10.1073/pnas.2008410117

2. Hegarty P-K, Kamat A, Zafirakis H, DiNardo A. BCG vaccination may be protective against Covid-19. Preprint March 2020. doi: 10.13140/RG.2.2.35948.10880

3. Dolgikh S. Further Evidence of a Possible Correlation Between the Severity of Covid-19 and BCG Immunization. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20056994

4. WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int. Accessed on January 14, 2021.

5. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478. doi: 10.1016/j.cmi.2019.04.020

6. Miller A, Reandelar M-J, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. Preprint March 2020. doi: 10.1101/2020.03.24.20042937

7. Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. medRxiv. Preprint May 2020. doi: 10.1101/2020.03.30.20048165

8. Shet A, Ray D, Malavige N, et al. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.01.20049478

9. Berg MK, Yu Q, Salvador CE, et al. Mandated BCG vaccination predicts flattened curves for the spread of COVID-19. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.05.20054163

10. K. Chumakov K., Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187–1188. doi: 10.1126/science.abc4262

11. Riccò M, Gualerzi G, Ranzieri S, Bragazzi NL. Stop playing with data: there is no sound evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for now). Acta Biomed. 2020;91(2):207–213. doi: 10.23750/abm.v91i2.9700

12. Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med. 2020;12(6):e12661. doi: 10.15252/emmm.202012661

13. Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316–317. doi: 10.1038/s41585-020-0325-9

14. BCG vaccines: WHO position paper — February, 2016. Weekly epidemiological record. 2018;93(6):73–96. (In Russ).

15. Global tuberculosis report 2020: executive summary (In Russ)..

16. A database of global BCG Vaccination policies and practices. BCG World Atlas. Available online: bcgatlas.org. Accessed on January 14, 2021.

17. Dayal D., Gupta S. Connecting BCG Vaccination and COVID-19: Additional Data. medRxiv. Preprint April 2020. doi: 10.1101/2020.04.07.20053272

18. Mangtani P, Nguipdop-Djomo P, Keogh RH, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess. 2017;21(39):1–54. doi: 10.3310/hta21390

19. Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis. 2005;9(10):1171–1173.

20. Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2016;16(2):219–226. doi: 10.1016/S1473-3099(15)00400-4

21. Aronson N, Santosham M, Comstock GW, et al. Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives A 60-Year Follow-up Study. JAMA. 2004;291(17):2086–2091. doi: 10.1001/jama.291.17.2086

22. Shvаrts YaSh, Stаvitskаya NV, Kudlay DA. BCG vaccination as protection from COVID-19: epidemiological and molecular biological aspectsю . Tuberculosis and Lung Diseases. 2020;98(5):6–14. (In Russ). doi: 10.21292/2075-1230-2020-98-5-6-14

23. Art RJW, Carvalho A, La Rocca C, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016;17(10):2562– 2571. doi: 10.1016/j.celrep.2016.11.011

24. Floc’h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol. 1976;127(2):173–186.

25. Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette–Guerin. J Infect Dis. 1977;136(2):1–175. doi: 10.1093/infdis/136.2.171

26. Wardhana EA, Datau EA, Sultana A, et al. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185–190.

27. Bacillus Calmette-Guérin vaccination to prevent infections of the elderly (ACTIVATE). US National Library of Medicine ClinicalTrials.gov. First Posted: September 28, 2017. Last Update Posted: January 11, 2021. Available online: https://clinicaltrials.gov/ct2/show/record/NCT03296423. Accessed on January 14, 2021.

28. Lopez-Campos G;, Hawthorne Christopher Hawthorne1, Valvano MSc; and Miguel A. ValvanoThe BCG dilemma: linear versus non-linear correlation models over the time of the COVID-19 pandemic. medRxiv. Preprint June 2020 doi: 10.1101/2020.06.13.20129569

29. Sayed A, Challa K, Arja S. Epidemiological Differences of COVID-19 Over the World. Cureus. 2020;12(9):e10316. doi: 10.7759/cureus.10316

30. Prasad R. Singh A, Gupta N. Tuberculosis and COVID 19 in India: Challenges and opportunities. Lung India. 2020;37(4):292– 294. doi: 10.4103/lungindia.lungindia_260_20

31. Ordog G-J. BCG Comments JAMA, by Ordog: SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. May 15, 2020. doi: 10.1001/jama.2020.8189comment

32. Reducing health care workers absenteeism in COVID-19 pandemic through BCG vaccine (BCG-CORONA). US National Library of Medicine ClinicalTrials.gov. First Posted: March 31, 2020. Last Update Posted: August 19, 2020. Available online:https://clinicaltrials.gov/ct2/show/NCT04328441. Accessed on January 14, 2021.

33. BCG vaccination to protect healthcare workers against COVID-19 (BRACE). US National Library of Medicine ClinicalTrials. gov. First Posted: March 31, 2020. Last Update Posted: October 22, 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT04327206. Accessed on January 14, 2021.

34. Guven R, Sasmaz MI, Eyupoglu G, Semerci SY. Do childhood measles and DTaP vaccination decrease the mortality rate caused by SARS CoV-2 in OECD countries? An Epidemiologic Study. Research Square. Preprint July 2020. doi: 10.21203/rs.3.rs-48106/v1

35. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202.

36. Chumakov MP, Voroshilova MK, Antsupova AS, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992;(11–12):37–40.

37. Cauchi S, Locht C. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases. Front Immunol. 2018;9:2872. doi: 10.3389/fimmu.2018.02872

38. Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25(12):1459–1467. doi: 10.1016/j.cmi.2019.08.011

39. Zheng MY, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi: 10.1038/s41423-020-0402-2

40. Götzinger F., Begoña Santiago-García Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020; 4(9): 653–61. doi: 10.1016/S2352-4642(20)30177-2

41. Sabir DK, Khwarahm NR, Ali SM, et al. Children Protection Against COVID-19 at the Pandemic Outbreak. J Immunological Sci. 2020;4(2):8–12. doi: 10.29245/2578-3009/2020/2.118.8